1 / 11

PolExGene ( Month 24-30)

PolExGene ( Month 24-30). Thomas Wirth University of Kuopio (UKU) Participant #: 9. Work packages. WP4: 4.1. Development of plasmids for polyplex incorporation. 4.4. Functionalisation of polymer membrane with polyplexes WP5: 5.1. Interaction between CPP-containing polyplexes and cells

geneva
Download Presentation

PolExGene ( Month 24-30)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PolExGene(Month24-30) Thomas Wirth University of Kuopio (UKU) Participant #: 9

  2. Work packages • WP4: • 4.1. Development of plasmids for polyplex incorporation. • 4.4. Functionalisation of polymer membrane with polyplexes • WP5: • 5.1. Interaction between CPP-containing polyplexes and cells • 5.2. Interaction between CIP-containing polymer membranes and cells. • WP7: • 7.2. Implantation of polymer membranes for cardiovascular diseases.

  3. Where are we now ? • WP4: • 4.1. Development of plasmids for polyplex incorporation. • VEGF • VEGF mutants • IK-17 • SEAP • 4.4. Functionalisation of polymer membrane with polyplexes • Production of recombinant proteins • WP5: • 5.1. Interaction between CPP-containing polyplexes and cells • Tested transfection efficiencies of different polyplexes • Tested different protocols • compared transfection efficiencies of polyplexes to viral vectors • 5.2. Interaction between CIP-containing polymer membranes and cells. • WP7: • 7.2. Implantation of polymer membranes for cardiovascular diseases.

  4. What was planned for months 24-30 • Evaluation of new polyplexes received from UGent • Testing of transfection protocol (UH.FP) • Sending stents to UGent • Evaluation of cell growth on polymers

  5. Evaluation of VT01, VT02-2 and VT09 polyplex-transfection Polyplex formation protocol Transfectionprotocol • Different charge ratio’s were prepared with DNA (EPI-SEAP plasmid) and VT01, VT02-2 and VT09 polyplexes • Charge ratios 4/1, 2/1 and 1/1 were tested • Diluted with Cationic Polymers Stock Solution (2,95 mM) • Polyplexes were prepared 2h before transfection • Total 600ng DNA was used in each well • 15000 cells were planted to 96-well plate • The following day cells were washed with 150µl PBS • 100µl serum-free medium was added to each well • 50µl polyplex-DNA solution was added to the cells • Incubate for 1h and 2h • Wash with 150µl PBS • Add 100µl full growth medium (F12/DMEM + serum + penstrep) • Incubate for 72h before measurement

  6. Measurement: Chemiluminescent SEAP Assay (Great EscAPe SEAP, Clonetech) • Start with 50µl cell culture medium (72h incubation after transfection) • briefly centrifuge and take supernatant to measurement (15µl) • Add 45µl 1x Dilution Buffer • Incubate 30min at +65ºC -> cool samples by placing on ice 2-3min • Add 60µl Assay Buffer and incubate 5min, RT • Add 60µl fresh CSPD Substrate working dilution and incubate for 10min • Measure with VectorII Luminometer

  7. VT01 polyplex • 2 Different time points and 3 different charge ratios were tested. • Charge ratio 4/1 didn’t give any effect on transfection • Charge ratio 2/1 worked with 2h transfection but not with 1h • Charge ratio 1/1 gave best transfection. • 1h transfection gave better transfection efficacy than 2h

  8. VT02-2 • Only 4/1 charge ratio showed any transfection efficiency. • 2h transfection time was superior compared to 1h.

  9. VT09 • Transfection efficiency was poor using VT09. • Only low levels of SEAP was measured from cell medium under any condition used.

  10. Conclusions • VT01 • Transfection was efficient with 1h transfection and 1/1 charge ratio • VT02-2 • Transfection was efficient with 2h transfection and 4/1 charge ratio • VT09 • Poor transfection using VT09

  11. What we will do • WP4: • 4.1. Development of plasmids for polyplex incorporation. • VEGF • VEGF mutants • IK-17 • SEAP • 4.4. Functionalisation of polymer membrane with polyplexes • Production of recombinant proteins • WP5: • 5.1. Interaction between CPP-containing polyplexes and cells • Tested transfection efficiencies of different polyplexes • Tested different protocols • compared transfection efficiencies of polyplexes to viral vectors • 5.2. Interaction between CIP-containing polymer membranes and cells. • WP7: • 7.2. Implantation of polymer membranes for cardiovascular diseases.

More Related